Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05511948
Other study ID # CT-212
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date August 18, 2022
Est. completion date March 7, 2023

Study information

Verified date October 2023
Source DermBiont, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, observer-blinded, vehicle-controlled multi-dose trial that examines the effect of twice daily application of 0.8% DBI-102 Gel, 4% Hydroquinone cream, and Vehicle Gel for 12 weeks in adults with Fitzpatrick Skin Types IV-V and a colorimeter L* measurement between 57.8 and 46.1.


Recruitment information / eligibility

Status Completed
Enrollment 75
Est. completion date March 7, 2023
Est. primary completion date March 7, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or Female at least 18 years of age. - Must be Fitzpatrick Skin Type IV-V and have an L* measurement between 57.8 and 46.1, using the Chromometer CM-700. - Ability to understand, agree to, and sign the study informed consent form (ICF). - Agree to discontinue all agents used to treat hyperpigmentation, aging or exfoliate the skin during the course of the study. Makeup and moisturizers are permitted. - Agree not to change their sun exposure at work, home, or leisure. - Technical ability and willingness to apply test articles. - Willing to allow digital photos of treatment and comparison areas to be taken and stored. Additional Inclusion Criterion for the solar lentigo Sub-Cohort: - At least 4 solar lentigos at least 4 mm in diameter present on each dorsal hand. Exclusion Criteria: - Positive urine pregnancy test, pregnant, lactating, or female of childbearing potential who does not agree to use an active method of birth control for the duration of the study. - Conditions at baseline that would interfere with evaluation of UV-tanned skin, especially other pigmentary disorders including, but not limited to, melasma or vitiligo affecting the treatment and comparison sites. - Presence of known concomitant diseases associated with the development of hyperpigmentation (e.g., thyroid, liver, adrenal). - Current tanning booth exposure or any kind of phototherapy within 3 months of Screening. - Current or past use of monobenzyl ether or hydroquinone (Benoquin) to depigment the skin. - Past or recent use of any skin bleaching treatment within 6 months of Screening. - A chemical peel within 3 months of Screening. - Laser or light-based treatment of the treatment areas within 3 months of Screening. - Use of any photosensitizing medications within the past 6 months of Screening, including psoralens, sulfonamide drugs, tetracycline antibiotics, thiazide diuretics, phenothiazines, coal tar and derivatives, and tricyclic antidepressants. - Any dermatological conditions that could interfere with clinical evaluations or any disease state or physical condition which might expose the subject to an unacceptable risk by study participation. - Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see Exclusion criteria 5 and 6). - Unwilling to discontinue applying any prescription or over the counter (OTC) topical product creams and ointments, other than makeup and moisturizers, on treatment area(s) at Baseline through their last day of study. - Treatment of any type of cancer within 6 months of Screening with the exception of superficial skin cancers such as basal cell or squamous cell carcinoma. - Known allergy to any of the test article(s) or any components in the test article(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure. - History of active atopic dermatitis, as diagnosed by a physician, requiring treatment within the past 2 years. - Unable to meet the study attendance requirements. - Any history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol. - Participation in any other trial of an investigational drug or device within 30 days prior to enrollment or participation in a research study concurrent with this study. Additional Exclusion Criterion for the Sub-Cohort - Any previous treatment for solar lentigos on the dorsal hands.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DBI-102
Topical application on dorsal hand and upper volar arm
Vehicle gel
Inactive comparator
Hydroquinone Cream
4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks

Locations

Country Name City State
El Salvador Zepeda Dermatologia Santa Tecla La Libertad

Sponsors (1)

Lead Sponsor Collaborator
DermBiont, Inc.

Country where clinical trial is conducted

El Salvador, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decrease in pigmentation based on melanin index Change in L* and ITA colorimetry measurements 12 weeks after first dose
Primary Decrease in pigmentation based on digital imaging Change as measured with Canfield RBX software analysis 12 weeks after first dose
Secondary Percent Change in Investigator Dynamic Grading Assessment (IDGA) Percent pigmentation differences between treated and contralateral Percent Change in Investigator Dynamic Grading Assessment (IDGA) At weeks 2,4,6,8,10, and 12
Secondary Proportion of subjects with Improved Investigator Dynamic Grading Scale (IDGA) Proportion of subjects with less pigmentation at treated sites vs contralateral untreated sites At weeks 2,4,6,8,10, and 12
See also
  Status Clinical Trial Phase
Completed NCT04586816 - Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging N/A
Completed NCT06000839 - A Safety and Effectiveness Study of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology) N/A
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT05362929 - Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color N/A
Completed NCT06031116 - Efficacy of Ceramic Soft Tissue Trimming Bur Versus Conventional Scalpel Technique in Ginigival Depigmentation Procedure N/A
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Active, not recruiting NCT05493280 - Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI N/A
Recruiting NCT06253455 - Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins N/A
Not yet recruiting NCT06080035 - The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation N/A
Completed NCT03457246 - Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy N/A
Completed NCT04619589 - Characterization of Dyschromic Hypertrophic Scar
Recruiting NCT05165524 - Brightening Cream and Lasers in Post-sclerotherapy Hyperpigmentation N/A
Not yet recruiting NCT06253468 - Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins N/A
Not yet recruiting NCT06268496 - Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins N/A
Completed NCT05423873 - A Multi-Center, Open-label Study Evaluate the Efficacy and Tolerability of a Dual Skincare Regimen Treatment for Facial Hyperpigmentation and Photodamaged Skin in Patients Exposed to Extrinsic Factors of Aging N/A
Completed NCT01149876 - Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots Phase 4
Completed NCT01542138 - Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation Phase 4
Completed NCT04704245 - Effectiveness of Epidermal Growth Factor-containing Ointment on the Solar Lentigines N/A
Completed NCT06189768 - A Study on Pigmentation Disorders in Children
Completed NCT06103461 - Fat Grafting an Ideal Filler For Contour Deformities With Hyperpigmentation On Face N/A